These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 16209703)

  • 21. Ascendancy of agricultural biotechnology in the Australian political mainstream coexists with technology criticism by a vocal-minority.
    Tribe D
    GM Crops Food; 2014 Jul; 5(3):229-40. PubMed ID: 25437242
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The Minderoo-Monaco Commission on Plastics and Human Health.
    Landrigan PJ; Raps H; Cropper M; Bald C; Brunner M; Canonizado EM; Charles D; Chiles TC; Donohue MJ; Enck J; Fenichel P; Fleming LE; Ferrier-Pages C; Fordham R; Gozt A; Griffin C; Hahn ME; Haryanto B; Hixson R; Ianelli H; James BD; Kumar P; Laborde A; Law KL; Martin K; Mu J; Mulders Y; Mustapha A; Niu J; Pahl S; Park Y; Pedrotti ML; Pitt JA; Ruchirawat M; Seewoo BJ; Spring M; Stegeman JJ; Suk W; Symeonides C; Takada H; Thompson RC; Vicini A; Wang Z; Whitman E; Wirth D; Wolff M; Yousuf AK; Dunlop S
    Ann Glob Health; 2023; 89(1):23. PubMed ID: 36969097
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A multidisciplinary review of the policy, intellectual property rights, and international trade environment for access and affordability to essential cancer medications.
    Baxi SM; Beall R; Yang J; Mackey TK
    Global Health; 2019 Sep; 15(1):57. PubMed ID: 31533850
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Potential impact of AUSFTA on Australia's blood supply.
    Bambrick HJ; Faunce TA; Johnston K
    Med J Aust; 2006 Sep; 185(6):320-3. PubMed ID: 16999673
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Government regulation of pricing and reimbursement of prescription medicines: results of a recent multi-country review.
    Kingham R; Wheeler J
    Food Drug Law J; 2009; 64(1):101-14. PubMed ID: 19998574
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The Pharmaceutical Benefits Scheme 2003-2004.
    Harvey KJ
    Aust New Zealand Health Policy; 2005 Jan; 2(1):2. PubMed ID: 15679896
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Transparency in pricing arrangements for medicines listed on the Australian Pharmaceutical Benefits Scheme.
    Robertson J; Walkom EJ; Henry DA
    Aust Health Rev; 2009 May; 33(2):192-9. PubMed ID: 19563308
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The Medicines Intelligence Centre of Research Excellence: Co-creating real-world evidence to support the evidentiary needs of Australian medicines regulators and payers.
    Pratt N; Camacho X; Vajdic C; Degenhardt L; Laba TL; Hillen J; Etherton-Beer C; Preen D; Jorm L; Donnolley N; Havard A; Pearson SA
    Int J Popul Data Sci; 2021; 6(3):1726. PubMed ID: 35784493
    [TBL] [Abstract][Full Text] [Related]  

  • 29. TRIPS, the Doha declaration and paragraph 6 decision: what are the remaining steps for protecting access to medicines?
    Kerry VB; Lee K
    Global Health; 2007 May; 3():3. PubMed ID: 17524147
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Balancing health and industrial policy objectives in the pharmaceutical sector: lessons from Australia.
    Morgan S; McMahon M; Greyson D
    Health Policy; 2008 Aug; 87(2):133-45. PubMed ID: 18295927
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Melanoma Vaccine--AVAX Technologies: DNP-VACC, M-Vax.
    BioDrugs; 2003; 17(1):69-72. PubMed ID: 12534322
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of a state hospital formulary on medicines utilisation in Australia.
    Iedema J
    Aust Health Rev; 2021 Dec; 45(6):704-717. PubMed ID: 34743785
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Balancing public health, trade and intellectual monopoly privileges: recent Australian IP legislation and the TPPA.
    Vines T; Crow K; Faunce T
    J Law Med; 2012 Dec; 20(2):280-94. PubMed ID: 23431847
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evidence-based decision-making within Australia's pharmaceutical benefits scheme.
    Lopert R
    Issue Brief (Commonw Fund); 2009 Jul; 60():1-13. PubMed ID: 19639714
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Beyond the black stump: rapid reviews of health research issues affecting regional, rural and remote Australia.
    Osborne SR; Alston LV; Bolton KA; Whelan J; Reeve E; Wong Shee A; Browne J; Walker T; Versace VL; Allender S; Nichols M; Backholer K; Goodwin N; Lewis S; Dalton H; Prael G; Curtin M; Brooks R; Verdon S; Crockett J; Hodgins G; Walsh S; Lyle DM; Thompson SC; Browne LJ; Knight S; Pit SW; Jones M; Gillam MH; Leach MJ; Gonzalez-Chica DA; Muyambi K; Eshetie T; Tran K; May E; Lieschke G; Parker V; Smith A; Hayes C; Dunlop AJ; Rajappa H; White R; Oakley P; Holliday S
    Med J Aust; 2020 Dec; 213 Suppl 11():S3-S32.e1. PubMed ID: 33314144
    [TBL] [Abstract][Full Text] [Related]  

  • 36. How the Trans Pacific Partnership Agreement could undermine PHARMAC and threaten access to affordable medicines and health equity in New Zealand.
    Gleeson D; Lopert R; Reid P
    Health Policy; 2013 Oct; 112(3):227-33. PubMed ID: 23992756
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Medicines and the media: news reports of medicines recommended for government reimbursement in Australia.
    Robertson J; Walkom EJ; Bevan MD; Newby DA
    BMC Public Health; 2013 May; 13():489. PubMed ID: 23687910
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The Experience and Effectiveness of Nurse Practitioners in Orthopaedic Settings: A Comprehensive Systematic Review.
    Taylor A; Staruchowicz L
    JBI Libr Syst Rev; 2012; 10(42 Suppl):1-22. PubMed ID: 27820153
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Costs to Australian taxpayers of pharmaceutical monopolies and proposals to extend them in the Trans-Pacific Partnership Agreement.
    Gleeson DH; Moir H; Lopert R
    Med J Aust; 2015 Apr; 202(6):306-8. PubMed ID: 25832153
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Financial costs associated with monopolies on biologic medicines in Australia.
    Gleeson D; Townsend B; Lopert R; Lexchin J; Moir H
    Aust Health Rev; 2019 Feb; 43(1):36-42. PubMed ID: 29116927
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.